US equities |
NVDA $186.64 ▲+2.78% MU $690.00 ▲+5.12% AMD $449.04 ▲+11.04% SPCX $134.27 ▲+8.62% AAPL $342.37 ▼-0.52% SNDK $835.06 ▲+3.55% MSFT $530.61 ▼-0.99% TSLA $358.22 ▲+4.23%
FinancialContent

Rigel Pharmaceuticals, Inc. - Common Stock (NQ:RIGL)

39.65 -6.06 (-13.26%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Rigel Pharmaceuticals, Inc. - Common Stock

News headline image
Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®
From AscellaHealth, LLC
Via GlobeNewswire
Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS
Via AB Newswire
Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical Trials
EQNX::TICKER_START (NASDAQ:TCBP),(NASDAQ:CRDF),(NASDAQ:CYAD),(NASDAQ:RIGL),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Investor Alert: Investigation over Potential Wrongdoing ↗
San Diego, CA -- (SBWIRE) -- 09/27/2021 -- Certain directors of Rigel Pharmaceuticals, Inc. are under investigation over possible breaches of fiduciary duties. 
Via SBWire
News headline image
NASDAQ:RIGL Shareholder Notice: Investigation over Possible Securities Laws Violations by Rigel Pharmaceuticals, Inc. ↗
San Diego, CA -- (SBWIRE) -- 08/30/2021 -- An investigation was announced over potential securities laws violations by Rigel Pharmaceuticals, Inc. in connection with certain financial statements. 
Via SBWire